Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: The DELPHINUS study

This phase 2 DELPHINUS study evaluated daratumumab (16 mg/kg IV) with chemotherapy in relapsed/refractory ALL/LL patients. While B-cell ALL cohorts showed no CRs, T-cell ALL/LL cohorts had CR rates of 41.7%-60.0%. Daratumumab was safe, achieved high HSCT rates (30%-75%), and supported successful bridging to transplantation in T-cell ALL/LL patients.